Hypofractionated palliative radiotherapy for bladder cancer.

Abstract

PURPOSE:

The aim of this study was to evaluate hematuria-free survival as well as acute and late toxicity after hypofractionated palliative radiotherapy for bladder cancer.

METHODS AND MATERIALS:

Between September 2004 and January 2013, 44 patients with biopsy-proven urothelial carcinoma of the bladder were irradiated according to a palliative schedule to a total dose of 34.5 Gy in six fractions of 5.75 Gy given once a week.

RESULTS:

After a mean follow-up of 10 months, 91% of patients were still hematuria free, with a mean hematuria-free survival of 13 months. Severe (≥ grade 3) acute and late urinary toxicity was observed in 9 and 19% of patients, respectively.

CONCLUSION:

This hypofractionated radiotherapy schedule appears to result in acceptable toxicity and manages successful and long-term palliation of hematuria in most patients.

• Authors: Piet Dirix, Sofie Vingerhoedt, Steven Joniau, Ben Van Cleynenbreugel, Karin Haustermans
• Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (Support Care Cancer) Vol. 24 Issue 1 Pg. 181-186 (Jan 2016) ISSN: 1433-7339 [Electronic] Germany
• PMID: 25975677 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Aged
• Aged, 80 and over
• Dose Fractionation, Radiation
• Female
• Hematuria (urine)
• Humans
• Male
• Middle Aged
• Urinary Bladder Neoplasms (mortality, radiotherapy)